Nuclear factor kappa-B and the heart
- PMID: 11499717
- DOI: 10.1016/s0735-1097(01)01377-8
Nuclear factor kappa-B and the heart
Abstract
Nuclear factor kappa-B (NFkappaB), a redox-sensitive transcription factor regulating a battery of inflammatory genes, has been indicated to play a role in the development of numerous pathological states. Activation of NFkappaB induces gene programs leading to transcription of factors that promote inflammation, such as leukocyte adhesion molecules, cytokines, and chemokines, although some few substances with possible anti-inflammatory effects are also NFkappaB regulated. The present article reviews basic regulation of NFkappaB and its activation, cell biological effects of NFkappaB activation and the role of NFkappaB in apoptosis. Evidence involving NFkappaB as a key factor in the pathophysiology of ischemia-reperfusion injury and heart failure is discussed. Although activation of NFkappaB induces pro-inflammatory genes, it has lately been indicated that the transcription factor is involved in the signaling of endogenous myocardial protection evoked by ischemic preconditioning. A possible role of NFkappaB in the development of atherosclerosis and unstable coronary syndromes is discussed. Nuclear factor kappa-B may be a new therapeutic target for myocardial protection.
Similar articles
-
Signal transduction through nuclear factor kappa B in ischemia-reperfusion and heart failure.Basic Res Cardiol. 2004 Jan;99(1):1-7. doi: 10.1007/s00395-003-0442-7. Epub 2003 Oct 30. Basic Res Cardiol. 2004. PMID: 14685699 Review.
-
Human adaptation to ischemia by preconditioning or unstable angina: involvement of nuclear factor kappa B, but not hypoxia-inducible factor 1 alpha in the heart.Eur J Cardiothorac Surg. 2008 Nov;34(5):976-84. doi: 10.1016/j.ejcts.2008.07.066. Epub 2008 Oct 7. Eur J Cardiothorac Surg. 2008. PMID: 18842422 Clinical Trial.
-
Myocardial protection by remote preconditioning: the role of nuclear factor kappa-B p105 and inducible nitric oxide synthase.Eur J Cardiothorac Surg. 2004 Nov;26(5):968-73. doi: 10.1016/j.ejcts.2004.06.015. Eur J Cardiothorac Surg. 2004. PMID: 15519191
-
[Clinical value of some factors of gene transcription in heart diseases].Kardiologiia. 2004;44(1):66-70. Kardiologiia. 2004. PMID: 15029150 Review. Russian.
-
A novel strategy for myocardial protection using in vivo transfection of cis element 'decoy' against NFkappaB binding site: evidence for a role of NFkappaB in ischemia-reperfusion injury.Circulation. 1997 Nov 4;96(9 Suppl):II-280-4; discussion II-285. Circulation. 1997. PMID: 9386111
Cited by
-
The protective effects of the proteasome inhibitor bortezomib (velcade) on ischemia-reperfusion injury in the rat retina.PLoS One. 2013 May 14;8(5):e64262. doi: 10.1371/journal.pone.0064262. Print 2013. PLoS One. 2013. PMID: 23691186 Free PMC article.
-
Use of cell permeable NBD peptides for suppression of inflammation.Ann Rheum Dis. 2006 Nov;65 Suppl 3(Suppl 3):iii75-82. doi: 10.1136/ard.2006.058438. Ann Rheum Dis. 2006. PMID: 17038479 Free PMC article. Review.
-
Role of nuclear factor-kappa B activation in acute ischaemia-reperfusion injury in myocardium.Br J Pharmacol. 2003 Mar;138(5):894-900. doi: 10.1038/sj.bjp.0705108. Br J Pharmacol. 2003. PMID: 12642391 Free PMC article.
-
The role of inflammation and infection in the pathogenesis and evolution of coronary artery disease.Curr Cardiol Rep. 2002 Jul;4(4):278-88. doi: 10.1007/s11886-002-0063-z. Curr Cardiol Rep. 2002. PMID: 12052267 Review.
-
Apigenin-7-O-β-d-(6″-p-coumaroyl)-glucopyranoside reduces myocardial ischaemia/reperfusion injury in an experimental model via regulating the inflammation response.Pharm Biol. 2020 Dec;58(1):80-88. doi: 10.1080/13880209.2019.1701043. Pharm Biol. 2020. PMID: 31887257 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
